KPV Peptide

Research

KPV peptide mechanism of action

Proposed KPV mechanisms (PepT1 uptake, NF-κB, IL-1β, melanocortin receptors) mapped to the studies that tested them, including negative results.

By the KPV Peptide editorial team · Last reviewed · Editorial review: approved by Ryan DeLauz (bulk sign-off in chat, 2026-11-11)

Short answer

KPV’s mechanism of action is not established. Cell studies report that it enters cells through the PepT1 transporter and lowers NF-κB and MAP-kinase signalling, while tests of the melanocortin receptors used by α-MSH came back negative. FDA concluded in 2026 that its molecular targets remain unknown[FDA briefing 2026].

Interactive research pathway

Proposed steps reported in cell and animal studies. Select any box to see the studies behind it. Dashed boxes are routes that were tested and not supported. FDA’s July 2026 review concluded that KPV’s molecular targets “remain unknown”.

Entry into cells

Intracellular signalling

Measured outputs

Tested, not supported

Uptake by PepT1 transporter

Radiolabelled-KPV uptake and competition assays in intestinal cell lines pointed to the di/tripeptide transporter PepT1; in mice lacking PepT1, KPV did not reduce tumour formation in a colitis-associated tumour model.

  • AnimalDalmasso 2008Caco2-BBE, HT29-Cl.19A and Jurkat cells; DSS and TNBS colitis models in mice
  • AnimalViennois 2016AOM/DSS colitis-associated tumour model in WT, hPepT1-transgenic and PepT1-KO mice; human colonic biopsies

Step 1: getting into the cell

The strongest uptake evidence comes from intestinal epithelial and T-cell lines, where KPV competed with a PepT1 substrate and showed saturable uptake. In the same study nanomolar KPV lowered NF-κB and MAP-kinase activation [Dalmasso 2008]. In mice without PepT1, KPV no longer reduced tumour formation in a colitis-associated tumour model, consistent with a role for the transporter [Viennois 2016]. PepT1 is mainly expressed in the small intestine, so this route explains intestinal-cell findings better than findings in skin or brain cells.

Step 2: NF-κB and its nuclear entry

NF-κB is a transcription factor that switches on many inflammatory genes. In bronchial epithelial cells, KPV itself was found in the nucleus, IκBα was stabilised, and the p65 subunit was less able to enter the nucleus. Competition assays suggested KPV interferes with the importin-α3 binding site on p65[Land 2012]. Lower NF-κB translocation was also measured in macrophage-like cells [Mandrika 2001].

Step 3: what was measured downstream

Downstream readouts include lower cytokine and chemokine output [Delgado 1998][Catania 1998], nitric oxide [Muceniece 2003], and, in recent studies, lower reactive oxygen species and NLRP3 inflammasome activity [Sung 2025][Bai 2026]. These are measurements in stimulated cultures: they describe what changed in the experiment, not a clinical effect.

Routes that were ruled out

α-MSH acts through melanocortin receptors and raises cAMP. KPV does not appear to: its anti-inflammatory effect in mouse peritonitis was not blocked by an MC3/4 antagonist and occurred without a cAMP rise [Getting 2003]; it did not bind melanocortin receptors in binding assays [Muceniece 2003]; and it remained active in MC1R-deficient mice [Kannengiesser 2008]. Keratinocyte studies also found no cAMP rise [Elliott 2004].

Frequently asked questions

Does KPV work through melanocortin receptors like α-MSH?

The studies that tested this say no: KPV did not bind melanocortin receptors or raise cAMP, and its effects persisted in MC1R-deficient mice and were not blocked by an MC3/4 antagonist.

What is the target of KPV?

Unknown. FDA’s 2026 review concluded that the molecular targets underlying KPV’s pharmacological effects remain unknown. PepT1 uptake and inhibition of p65 nuclear import are leading proposals from cell studies.

References

  1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PubMed 18061177 · doi:10.1053/j.gastro.2007.10.026[Animal, grade C]
  2. Viennois E, Ingersoll SA, Ayyadurai S et al. (2016). Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. PubMed 27458604 · doi:10.1016/j.jcmgh.2016.01.006[Animal, grade C]
  3. Land SC (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. PubMed 22837805[In vitro, grade D]
  4. Mandrika I, Muceniece R, Wikberg JE (2001). Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: evidence for dual mechanisms of action. Biochem Pharmacol. PubMed 11239505 · doi:10.1016/s0006-2952(00)00583-9[In vitro, grade D]
  5. Barcellini W, Colombo G, La Maestra L et al. (2000). Alpha-melanocyte-stimulating hormone peptides inhibit HIV-1 expression in chronically infected promonocytic U1 cells and in acutely infected monocytes. J Leukoc Biol. PubMed 11073109[In vitro, grade D]
  6. Sung J, Ju SY, Park S et al. (2025). Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue Cell. PubMed 40073467 · doi:10.1016/j.tice.2025.102837[In vitro, grade D]
  7. Bai JS, Kim RW, Li Y et al. (2026). Lysine-Proline-Valine attenuates oxidized low-density lipoprotein-induced foam cell formation and inflammatory responses in RAW264.7 macrophages. Tissue Cell. PubMed 42854645 · doi:10.1016/j.tice.2026.104036[In vitro, grade D]
  8. Lee JY, Lee J, Jung WK et al. (2026). Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. Cytotechnology. PubMed 42064835 · doi:10.1007/s10616-026-00967-z[In vitro, grade D]
  9. Delgado R, Carlin A, Airaghi L et al. (1998). Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia. J Leukoc Biol. PubMed 9620667 · doi:10.1002/jlb.63.6.740[In vitro, grade D]
  10. Catania A, Garofalo L, Cutuli M et al. (1998). Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients. Peptides. PubMed 9700761 · doi:10.1016/s0196-9781(98)00055-2[Ex vivo, grade D]
  11. Muceniece R, Krigere L, Süli-Vargha H et al. (2003). Effects of alpha-melanotropin C-terminal tripeptide analogues on macrophage NO production. Peptides. PubMed 12895656 · doi:10.1016/s0196-9781(03)00128-1[In vitro, grade D]
  12. Getting SJ, Schiöth HB, Perretti M (2003). Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. PubMed 12750433 · doi:10.1124/jpet.103.051623[Animal, grade C]
  13. Uehara Y, Shimizu H, Sato N et al. (1992). Carboxyl-terminal tripeptide of alpha-melanocyte-stimulating hormone antagonizes interleukin-1-induced anorexia. Eur J Pharmacol. PubMed 1330615 · doi:10.1016/0014-2999(92)90738-p[Animal, grade C]
  14. Kannengiesser K, Maaser C, Heidemann J et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. PubMed 18092346 · doi:10.1002/ibd.20334[Animal, grade C]
  15. Elliott RJ, Szabo M, Wagner MJ et al. (2004). alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. PubMed 15102092 · doi:10.1111/j.0022-202X.2004.22404.x[In vitro, grade D]
  16. U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee (2026-07-23). FDA Briefing Document: KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate). Source[retrieved 2026-11-11]